Valuation: StemCell Institute Inc.

Market Cap 7.8B 49.09M 42.05M 39.35M 36.02M 67.59M 4.7B 68.49M 465M 181M 2.36B 184M 180M P/E 2026
49.6x
P/E 2027 * 71.1x
Enterprise Value 7.8B 49.09M 42.05M 39.35M 36.02M 67.59M 4.7B 68.49M 465M 181M 2.36B 184M 180M EV / Sales 2026
2.74x
EV / Sales 2027 * 2.52x
Free-Float
22.67%
Yield 2026 *
-
Yield 2027 * -
1 week+2.38%
Current month+9.15%
1 month+6.02%
3 months+20.53%
6 months-10.51%
Current year-2.27%
1 week 757
Extreme 757
775
1 month 699
Extreme 699
775
Current year 627
Extreme 627
976
1 year 627
Extreme 627
1,025
3 years 627
Extreme 627
2,776
5 years 627
Extreme 627
3,365
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 2016-05-31
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 53 2013-08-31
Director/Board Member 81 2015-05-31
Director/Board Member 66 2020-05-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.38%-24.39%-69.02% 49.16M
-0.67%-4.26%+30.23%+38.67% 120B
+5.64%+6.06%+6.17%+56.17% 87.96B
+1.28%+4.26%+33.02%+83.90% 26.63B
-0.25%+4.12%-3.92%-8.54% 22.17B
+3.00%+4.80%+58.28%+291.97% 21.95B
+1.48%+3.51%-9.32%+14.59% 14.2B
-1.83%-2.19%-7.94%-8.92% 12.66B
-0.81%-3.47%+26.34%+70.60% 11.18B
+2.54%+4.26%-3.64%+38.16% 10.19B
Average +1.04%+0.88%+10.48%+50.76% 32.67B
Weighted average by Cap. +1.61%-1.14%+19.15%+59.05%

Financials

2026 2027 *
Net sales 2.87B 18.05M 15.46M 14.47M 13.25M 24.86M 1.73B 25.19M 171M 66.67M 868M 67.79M 66.31M 3.1B 19.5M 16.7M 15.63M 14.31M 26.85M 1.87B 27.2M 185M 72.01M 937M 73.22M 71.63M
Net income 180M 1.13M 970K 907K 831K 1.56M 108M 1.58M 10.72M 4.18M 54.42M 4.25M 4.16M 110M 692K 593K 555K 508K 953K 66.2M 965K 6.55M 2.56M 33.26M 2.6M 2.54M
Net Debt - -
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
26-08-21 JP¥775.00 0.00% 14,900
26-08-20 JP¥775.00 +0.65% 4,300
26-08-19 JP¥770.00 -0.39% 4,600
26-08-18 JP¥773.00 +0.65% 10,200
26-08-17 JP¥768.00 +1.45% 10,100

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7096 Stock